



The Gut Microbiota-Host Partnership as a Potential Driver of Kawasaki Syndrome

Susanna Esposito^{1*}, Ilaria Polinori¹ and Donato Rigante^{2,3,4}

¹ Pediatric Clinic, Department of Surgical and Biomedical Sciences, Università degli Studi di Perugia, Perugia, Italy, ² Institute of Pediatrics, IRCCS, Rome, Italy, ³ Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy, ⁴ Università Cattolica Sacro Cuore, Rome, Italy

OPEN ACCESS

Edited by:

Kyung-Yil Lee,
The Catholic University of Korea,
South Korea

Reviewed by:

Valerio Iebba,
Istituto Pasteur Italia, Italy
Jeong Jin Yu,
University of Ulsan College of
Medicine, South Korea

*Correspondence:

Susanna Esposito
susanna.esposito@unimi.it

Specialty section:

This article was submitted to
Pediatric Infectious Diseases,
a section of the journal
Frontiers in Pediatrics

Received: 03 February 2019

Accepted: 15 March 2019

Published: 05 April 2019

Citation:

Esposito S, Polinori I and Rigante D
(2019) The Gut Microbiota-Host
Partnership as a Potential Driver of
Kawasaki Syndrome.
Front. Pediatr. 7:124.
doi: 10.3389/fped.2019.00124

Kawasaki syndrome (KS) is a necrotizing vasculitis of small- and medium-sized vessels mostly affecting children under 5 years of age; a host of clinical and epidemiological data supports the notion that KS might result from an infectious disease. However, many efforts have failed to identify a potentially universal trigger of KS. The contribution of the intestinal microbial community—called the “microbiota”—to KS has been evaluated by an increasing number of studies, though limited to small cohorts of patients. Differences in the microbiota composition were found in children with KS, both its acute and non-acute phase, with abnormal colonization by *Streptococcus* species in the intestinal tract and a wider presence of Gram-positive cocci in jejunal biopsies. In particular, a higher number of Gram-positive cocci (of the genera *Streptococcus* and *Staphylococcus*), *Eubacterium*, *Peptostreptococcus*, and HSP60-producing Gram-negative microbes have been found in the stools of KS children, and their effects on the antigenic repertoire of specific T cells and V β 2 T cell expansion have been assessed. Conversely, *Lactobacilli* were lacking in most children with KS compared with other febrile illnesses and healthy controls. All studies available to date have confirmed that an imbalance in the gut microbiota might indirectly interfere with the normal function of innate and adaptive immunity, and that variable microbiota interactions with environmental factors, mainly infectious agents, might selectively drive the development of KS in genetically susceptible children. Further investigations of the intestinal microflora in larger cohorts of KS patients will provide clues to disentangle the pathogenesis of this disease and probably indicate disease-modifying agents or more rational KS-specific therapies.

Keywords: Kawasaki syndrome, infection, innovative biotechnologies, microbiota, personalized medicine, child

INTRODUCTION

The most insidious primary vasculitis in childhood is Kawasaki syndrome (KS), an acute multi-systemic illness which predominantly affects children under 5 years of age (1). Currently, this disorder of unknown etiology remains the main cause of acquired heart disease among children living in developed countries, where rheumatic fever has been surpassed (2, 3). This condition was originally called “mucocutaneous lymph node syndrome” by Dr. Tomisaku Kawasaki, who was its discoverer, and was thought to be a benign children’s disease; nowadays, the illness has

been described worldwide in children of every ethnicity following the presence of fever persisting (at least) 5 days together with (at least) 4 of the 5 following signs: bilateral conjunctival injection, oropharyngeal inflammation, abnormalities of hands and feet, polymorphous exanthema, and non-purulent cervical lymphadenopathy, usually unilateral (4). Several years after the first description, fatalities occurred among children with KS younger than 2 years living in Japan, prompting clinicians to reconsider KS's long-term risks related to systemic and necrotizing effects on the vascular endothelium of small- and medium-sized arteries, which have been acknowledged in all guidelines related to the management of KS (5, 6). The most relevant sequelae of KS include variable degrees of damage within coronary arteries in combination with angina, myocardial infarction, ischemic cardiomyopathy, and sudden death; these complications should be preventable with a timely treatment of high-dose intravenous immunoglobulin (IVIG), which is the recommended therapeutic strategy in KS (7). Higher acute phase reactants and younger age at onset of KS are nodal points in determining, respectively, a failure in the response to IVIG and an increased occurrence of coronary artery abnormalities (8). The prediction of IVIG resistance is also crucial in KS patients, as recognizing these high-risk children should consent to start an intensified treatment protocol combined with IVIG to prevent coronary injuries (9).

KS incidence varies widely among different ethnic groups; for instance, in the United Kingdom it has stabilized and remains low at 2.8 per 100,000 population under the age of 20 years. However, general practitioners should be aware that the condition occurs throughout childhood and across the seasons, and—given the potential cardiovascular sequelae—KS should be considered in all children with persistent fever, even in older children and adolescents (10). KS is most prominently recognized in Japan, Korea, and Taiwan, reflecting increased genetic susceptibility among Asian populations. A recent study reported an incidence of ~240 per 100,000 children under 4 years of age in Japan (11). There is still much controversy about the etiology of KS, though epidemiologic and clinical data suggest that KS might originate from an abnormal response to undisclosed infectious diseases in genetically susceptible children (12). There is no agreement whether KS-related infectious agents are of viral, bacterial or fungal origin (13), and the underlying immune mechanisms behind KS have not been completely highlighted, remaining only partially known. The absence of a proven unambiguous cause of KS has induced the scientific community to pay attention to other environmental hypothetical triggers, and in particular the composition of the resident intestinal flora as a potential contributor to KS has been evaluated by different research groups.

The main aim of this review was to analyze the relationship between the microbial community, or the “microbiota,” and the overall impact of bacterial or viral infections in the potential development of KS. Scientific papers have been searched from the electronic databases of PubMed until January 2019; the retrieving words were “Kawasaki disease,” “Kawasaki syndrome,” “microbiota,” and “microbiome”; additional reports were identified and analyzed through the specific references

cited in the retrieved papers. Only papers published in English and those showing evidence-based data were included in our evaluation.

EVOLUTION OF THE MICROBIOTA IN CHILDREN

The microbiota, a microbial community of trillions of microorganisms and at least 1,000 different bacterial species, some eukaryotic fungi and viruses, and which covers every surface of the human body, plays a contributory role in many infections, immune-mediated disorders, rheumatologic diseases, and disorders of the nervous system. The microbiome, on the other hand, is the collection of the whole genome sequences of those microorganisms, consisting of more than 5,000,000 genes (14, 15). In particular, the gut microbiota is strictly linked to the chronological age of each individual and modulates host physiology and metabolism through different mechanisms.

Each stage of human life is characterized by a specific intestinal microbial composition: the microbiota that initially colonizes the fetus' intestinal tube consists of aerobic organisms such as *Enterococcus* and *Streptococcus*, is then gradually replaced by anaerobes such as *Bifidobacterium* and *Lactobacillus* and finally reaches the adult composition dominated by *Bacteroides* and Firmicutes (16, 17). The fetal microbiota is prone to be conditioned by the type of delivery; the mother's vaginal flora is a relevant source of *Lactobacillus*, *Prevotella*, and *Bifidobacterium*. Conversely, a cesarean delivery delays contact with these species, producing a similar-to-skin flora, dominated by Staphylococci (18). The feeding regimens and food supplements also play a role in modifying the resident flora; a greater complexity is normally seen in infants fed with formula, rather than in breastfed babies who have an “adult-like” structured microbiota with a population rich with Bifidobacteria, Lactobacilli, and *Bacteroides* (18). The infant gut microbiota is variable in composition over time and highly changeable during the first year of life, being influenced by specific bacteria to which a baby happens to be exposed, as shown by the resemblance of infants' stool microbial community with mothers' milk and vaginal samples (19). Thereafter, the infant's intestinal tract progresses toward an extremely dense colonization, ending with a mixture of microbes that is broadly very similar to an adult's intestine. During adulthood, the gut microbiota becomes stable and this intestinal homeostasis remains in equilibrium with the host. Food habits influence the composition of the whole intestinal microbiota, as testified by the lower prevalence of *Bacteroides* in those suffering from malnutrition and by different microbiota changes occurring in children with diet-related diseases, such as allergies and obesity (19).

Arumugam et al. identified three distinct enterotypes, namely *Bacteroides*, *Prevotella*, and *Ruminococcus*, which reflect many individual alimentary profiles: *Bacteroides* correlates to a high-fat or high-protein regimen, whereas *Prevotella* is associated with higher consumption of fibers and simple sugars (20). More recent data have consented to unify *Bacteroides* and *Ruminococcus* enterotypes due to the large similarity between the two (21). It is

well-established that early events of birth, environmental factors during infancy, sex hormones, diet, body weight, and use of antibiotics can undoubtedly differentiate the composition of the microbiota (22, 23). There are no ideal culture methods to give us a real overview of the complete intestinal flora, though molecular methods, e.g., DNA microarrays with comprehensive coverage of most bacterial taxa represented in the available database of small subunit ribosomal RNA gene sequences, should allow the characterization of most taxonomic groups of the intestinal bacteria (24, 25).

ROLE OF THE BACTERIAL FLORA IN CHILDHOOD DISEASES

The ancient symbiosis between the human gastrointestinal tract and its resident microbiota involves diverse reciprocal interactions between the microbiota itself and the host, with relevant consequences for human health and physiology. The quality of the microbial flora has an impact on the maintenance of health and also on prevention of diseases. Indeed, there are numerous roles carried out by the intestinal ecosystem, as the stimulation of angiogenesis, control of host fat storage and protection against other pathogens. In particular, the microbiota influences the formation and progress of regulation of both innate and adaptive immunity in close interaction with the intestinal mucosal immune system. The intestinal mucosa may be considered as an immunological niche as it hosts a complex immune-functional organ comprised by T cell subpopulations, neutrophils, macrophage-dendritic cells, enterocytes (that possess tight intercellular junctions) and their related anti- and pro-inflammatory cytokines as well as several other mediators of inflammation or antimicrobial peptides, defensins, and secretory immunoglobulin A (IgA) (26). The intestinal microbiota may also have direct or indirect effects on the natural course of viral infections, interacting with viral particles and leading to differences in either pathogenicity or anti-viral immune response through recruitment and activation of several T cell subpopulations (18). A large amount of data has also depicted the relevance of gut microbiota-immune system cross-talk in several diseases, and indeed an “imbalance” of the intestinal flora has been shown in patients with atopic diseases and various non-infectious diseases, including metabolic disorders, chronic inflammatory bowel disease (IBD), irritable bowel syndrome, pancreatic diseases, atherosclerosis, and rheumatoid arthritis (27, 28). Furthermore, the gut microbiota, interacting with pattern recognition receptors (PRRs), signaling receptors that can recognize molecular structures of pathogens and activate the cascade of innate immunity, plays a crucial role in maintaining the homeostasis of the innate immunity responses in the gut, and leaks in the intestinal mucosal barrier lead to the translocation of bacterial products into portal circulation which promotes systemic inflammation (29). In addition, the microbiota can maintain a segregation between intestinal mucosa and bacteria via PRRs, though pathogens might usurp innate signals to their advantage (30).

Several immunologic, metabolic and nutritional processes are normally controlled by the intestinal microbiota, and changes in the local microbial communities have been linked to chronic low-grade inflammation (31). Alexander et al. demonstrated that the microbiota has specific effects on adaptive immunity, such as the induction of regulatory effector CD4+ cells and production of cytokines and antimicrobial factors, influencing the individual response to various environmental stimuli, as seen in IBD, Crohn’s disease and ulcerative colitis (32). In a recent work, Schwartz et al. have shown microbiota changes characterized by decreased numbers of *Faecalibacterium prausnitzii* and increased numbers of *Escherichia coli* in IBD (33). Additionally, in celiac disease De Palma et al. have described a difference in the microbiota composition with a reduction of *Bifidobacterium*, *Clostridium histolyticum*, *Clostridium lituseburense*, *Faecalibacterium prausnitzii*, and an abundance of *Bacteroides* and *Prevotella* strains (34). A significantly higher biodiversity in coeliac children’s duodenal mucosa was demonstrated by Schippa et al. who also highlighted that the possible pathophysiological role of such microbial differences needs further characterization (35). In addition, many immune phenomena were shown to deteriorate under the effect of changes in the microbiota, as revealed by the correlation among intestinal bacterial overgrowth, increased permeability, and development of non-alcoholic steatohepatitis (36).

Much interest has also been paid to the role of the microbiome in the development of “sterile” inflammation, and recent studies have proved that either depletion of the microbiota or changes in the diet and in the gut microbiome might lead to the improvement of inflammasome-mediated manifestations of autoinflammatory disorders, which are caused by dysregulation of specific components of innate immunity (37). These diseases can be subdivided into monogenic and multifactorial disorders, with the former being caused by mutations of genes involved in the regulation of the innate immune system and the latter by a combination of genetic background and environmental factors (38–40). Given the evidence for the role of the intestinal microbiota in the inflammatory state of IBD, atopic diseases and numerous non-infectious diseases, it has been speculated that intestinal microbial agents might also play a trigger role in the development of other inflammatory disorders which do not have a clearly defined etiology, such as KS.

UNSOLVED PROBLEMS ABOUT THE ETIOLOGY OF KAWASAKI SYNDROME

The etiology of KS remains obscure, although clinical and epidemiological features suggest a primary infectious cause. Indeed, a self-limited and generally nonrecurring illness that manifests itself by fever, rash, mucositis, conjunctival injection, and cervical adenopathy fits well with an infection. More precisely, clinical features of KS resemble some peculiar infectious diseases, such as streptococcal infections, staphylococcal toxic shock syndrome, and atypical measles (12, 13). Additionally, age distribution, winter-spring seasonality, high rates of KS in siblings, and occurrence of community

outbreaks are suggestive of a transmissible childhood disease, though many efforts with conventional bacterial and viral cultures and serological methods as well as animal inoculation studies have failed to identify a final unique infectious agent of KS (41). Reported non-infectious factors associated with KS include carpet shampoo, preexisting eczema, environmental pollution, and house dust mites (42). The higher incidence of KS in Asian populations, presence of familial clustering, and elevated risk of recurrence vs. the risk of a first episode in KS-naïve children are all strong evidence of a genetic contribution to KS susceptibility, probably in association with an infectious trigger (43, 44). However, KS does not appear easily transmittable and does not respond to any antibiotics: these characteristics should contradict a primitively infectious pathogenesis of the illness.

The most current theory about the pathogenesis of KS is that the disease results from an exaggerated immune response toward environmental stimuli occurring in a genetically susceptible child (13). The prominent role played by the immune system in KS is confirmed by the high number of studies revealing the activation of neutrophils and multiple immune cells with overproduction of pro-inflammatory cytokines, including tumor necrosis factor (TNF)- α (45, 46). Manlhiot et al. have very recently proposed a new pathogenetic model of KS in which the disease risk is determined by concurrent interacting processes: genetic susceptibility, habitual exposure to allergens, atmospheric biological particles, and infectious agents (47). A study exploring the immune responses during the acute phase of KS showed increased levels of lipopolysaccharide (LPS) bound to the surfaces of circulating neutrophils via CD14 receptor and found markedly increased levels of the soluble CD14 in the plasma (48). Furthermore, Chen et al. (49) demonstrated that NLRP3 inflammasome activation is associated with the development of coronary arteritis in a mouse model of KS, and that infusion of visfatin, a major injurious adipokine, can activate NLRP3 inflammasome and increase interleukin (IL)-1 production, leading to enhanced endothelial dysfunction. These novel molecular mechanisms of vasculitis mediated by inflammasome activation open more specifically the road to innate immunity pathways in the interpretation of KS (49, 50).

THE COMPLEX RELATIONSHIP OF KAWASAKI SYNDROME AND INFECTIONS

Unchallengeable proof that an infection is the starting point of KS is not available. Different epidemiologic studies have supported this hypothesis, based on documented infections by various microorganisms in many cases of KS. Further clues are the occurrence of KS in epidemics, higher incidence during spring and winter and early age at which the disease might be acquired, that is 6 months to 5 years (5). Striking perturbations of many immune pathways occur during the acute phase of KS, which determines a multi-cytokine cascade in the vascular endothelium with focal disruption of small- and medium-sized vessels. However, the exact key steps leading to coronary arteritis are still far from being clarified, though endothelial cell activation; prolonged start-up of neutrophils, CD68⁺

monocyte/macrophages and CD8⁺ lymphocytes; production of oxygen intermediates and lysosomal enzymes; and oligoclonal IgA response by plasma cells all appear to be involved (45, 46, 51–53).

The contribution of viruses to KS has been suggested by ultrastructural studies which found cytoplasmic inclusion bodies containing RNA of viral origin in the bronchial epithelia (54) as well as by studies revealing the detection of intracytoplasmic inclusion bodies containing viral proteins and nucleic acid aggregates (55, 56). Recent investigations have supported the hypothesis that immune responses in KS are oligoclonal rather than polyclonal (as found typically in superantigen-driven responses), and that IgA plasma cells play a crucial role. Indeed, higher levels of IgA have been found in the vasculature of patients with previous KS, indicating an antigen-driven response against an etiologic agent which might have a respiratory or gastrointestinal portal of entry (57).

About half of all KS patients might have one or more respiratory viruses detected by polymerase chain reaction, without any particular predominance, but a positive respiratory viral test or presence of respiratory symptoms at the time of presentation should not be used to exclude the diagnosis of KS (58). Other studies have investigated a potential relationship of KS with coronaviruses, though without finding definite proof of cause and effect (59, 60). Many viruses have been suggested to be implicated in the pathogenesis of KS, such as adenovirus, parvovirus B19, rotavirus, H1N1 influenza virus, Epstein-Barr virus, herpesvirus 6, coxsackie B3 virus, parainfluenza virus type 3, measles virus, dengue virus, human immunodeficiency virus, and varicella-zoster virus, but no significant differences emerged from case-controlled studies (61–69). One of the most difficult infections that are harder to distinguish from KS is caused by adenovirus, due to its frequent incidental detection in KS patients and frequent laboratory finding of increased inflammatory markers (70). In particular, adenovirus has been detected in 8.8 and 25% of cases with complete and incomplete KS, respectively, by Jaggi et al. (71). There are reports that have emphasized the possible relationship of cytomegalovirus (in one child from Turkey) and human bocavirus 1 (in a French cohort of 32 patients) with KS through serologic tests and molecular techniques, but this link might be only casual and misleading (72, 73).

Regarding the bacterial origin of KS, it is debated if the infectious agents might be conventional bacteria or bacteria with superantigen activity. Superantigens (SAGs) are the most powerful T cell mitogens ever discovered, with potent immunostimulatory actions that simultaneously activate the major histocompatibility complex class II molecules and T cell receptors, leading to massive activation of various immune cells. Many studies have investigated the involvement of SAGs in KS. One of the first studies showed the selective expansion of T cell receptor (TCR) V β 2-bearing T cells in the peripheral blood of children during the acute phase of KS (74). In addition, Leung et al. isolated Staphylococci and Streptococci that produced SAGs (toxic shock syndrome toxin-1 or TSST-1, SST-1, SEB, SEC, SPEB, and SPEC) from the throat, rectum and groin in 25 of 45

patients with untreated KS (56%) in comparison with 13 of 37 control patients (35%) (75).

Matsubara et al. conducted a case-control study with a serological approach based on enzyme-linked immunosorbent assay and measured serum antibodies against staphylococcal enterotoxins, including TSST-1, and streptococcal pyrogenic exotoxin (SPE), such as SPE-A. They showed that KS patients had significant elevation of IgM antibodies against one or more of five SAGs throughout the first to the fourth disease week (76). In a further paper the same authors analyzed the studies regarding the role of SAGs produced by *Staphylococcus aureus* and *Streptococcus pyogenes* in the pathogenesis of KS, finding numerous SAGs implicated, which brought the total number of the known staphylococcal SAGs to over 20 and streptococcal SAGs to 12 (77).

The most recent work that analyzed the relationship between SAGs and KS examined different SAG derived from *Streptococcus pyogenes* in the stools of patients with KS. Stool specimens were obtained from 36 patients with KS during the acute phase and 26 age-matched healthy children. The authors examined genes related to five Sags—SPE-A, SPE-C, SPE-G, SPE-J, and TSST-1—using polymerase chain reaction; throat and stool cultures were assessed to evaluate the presence of *Streptococcus pyogenes* and *Staphylococcus aureus* in KS patients. They reported that at least one of the SAG-related genes was detected more frequently in the stools of children with KS (78). Furthermore, among 358 patients with KS, 54 developed concurrent pneumonia and 12 of these (22.2%) had high titers of anti-*Mycoplasma pneumoniae* antibody (>1:640), suggesting a potential role of *Mycoplasma pneumoniae* in KS and the importance of anti-*Mycoplasma* treatment (79).

Another study has reported a possible role of fungal infections in the development of KS in Japan, San Diego, and the island of Hawaii through an active role of tropospheric wind patterns leaving from Central Asia, in which toxins of *Candida* species are aerosolized (80). In addition, due to the observation that *Candida albicans*-derived substances, such as *Candida albicans* water-soluble fraction (CAWS), induce a coronary arteritis in mice similar to that observed in KS, Sato et al. evaluated the role of a free- β -glucan diet on CAWS-induced vasculitis and found that quality of diet might affect the progression of systemic vasculitis (81). CAWS should act as a pathogen-associated molecular pattern in mice and activate lectin pathway of complement by binding to mannose-binding lectin and inducing an acute inflammatory reaction in the vascular system (82, 83).

WHAT IS KNOWN ABOUT MICROBIOTA AND KAWASAKI SYNDROME

There are three main reasons that led us to postulate a role of the microbiota in KS. The first is the unsatisfactory microbiological data that limited the association between infections and KS and a lack of evidence of any clear relationship between one or more pathogens with this illness. Second, the most frequent bacteria or viruses associated with KS have a higher prevalence in the overall pediatric population, but only a limited number of children will develop the disease. Third, the association

of genetic predisposition and environmental factors in the pathogenetic process of KS makes KS itself similar to other multifactorial diseases.

Currently, the majority of data has found that the composition of the gut microbiota in KS patients differs from healthy subjects. Lee et al. have postulated that the immune system should lose tolerance toward a part of the resident intestinal flora and that environmental factors, i.e., a Western lifestyle or improved public hygiene systems, could transform the commensal flora into a pathogen one, as observed in different gastrointestinal disorders (84).

A recent study about the resident flora and KS was focused on throat flora. Horita et al. (85) assumed that throat flora could be a reservoir of microorganisms triggering KS and, following this hypothesis, they investigated throat microorganisms of KS patients for their content and individual SAG activity. In particular, they collected throat swabs at the start of IVIG infusion in 21 KS patients and compared them with non-KS controls (displaying other febrile illnesses). The results showed no difference in the throat flora between KS and febrile controls even in the mean mitogenic activity of bacteria isolated (85).

The gastrointestinal tract could be one of the primary sites of entry of bacterial toxins in children with KS, and a perturbation in the intestinal microbiota has been linked to the disease's pathophysiology in another study by Yamashiro et al. (86) who investigated the microflora of the small intestine in 15 Japanese patients with KS. The range of bacterial species isolated from jejunal biopsies was characterized by a wider variety of Gram-positive cocci in the acute phase of KS. Notably, 5 kinds of streptococci (*Streptococcus salivarius*, *Streptococcus mitis*, *Streptococcus oralis*, *Streptococcus sanguis*, and *Gemella haemolysans*) and 2 kinds of staphylococci (*Staphylococcus capitis* and *Staphylococcus hyicus*) were isolated only from KS patients, suggesting that some antigens inducing a delayed-type hypersensitivity reaction in the mucosa might inundate the body by breaching the barrier of the small intestinal mucosa of KS patients (86). In fact, Nagata et al. (87) investigated cell surface phenotypes of mononuclear cells and enterocytes in the jejunal mucosa of 16 Japanese patients with KS and in 10 patients with diarrhea due to cow's milk protein intolerance. Both HLA-DR+CD3+ and DR+CD4+ cells were significantly increased, and CD8+ cells significantly reduced in the lamina propria of KS patients during the acute phase compared with patients with cow's milk protein intolerance. These cell patterns returned to normal in the convalescent phase of KS. The authors concluded that a delayed-type hypersensitivity reaction was indeed present in the small intestinal mucosa of KS patients (87).

Due to the fact that the gastrointestinal tract is the largest interface between microbial factors and their host, containing the largest proportion of bacteria and the largest amount of lymphoid tissue in the body, it was hypothesized by Eladawy et al. that the intestinal milieu could be altered in children with KS, and indeed KS patients have a higher incidence of gastrointestinal symptoms and complications (88). Specifically, Takeshita et al. (89) evaluated 20 patients with KS, 20 patients with acute febrile diseases and 20 healthy children, finding that the incidence of *Lactobacilli* isolated from KS patients (2/20,

10%) was significantly lower ($p < 0.001$) than in the other cohorts. Moreover, no significant differences in the presence of *Staphylococcus*, *Streptococcus*, *Enterococcus*, *Enterobacteriaceae*, *Bifidobacterium*, *Clostridium*, *Veillonella*, or *Bacteroides* were found among the three groups. Conversely, the presence of *Eubacterium* and *Peptostreptococcus* was significantly higher in KS patients than in patients with other febrile diseases ($p < 0.01$ and $p < 0.05$, respectively), though no significant differences were observed between KS patients and healthy children (89). This observation confirmed that the majority of *Lactobacillus* species are anti-inflammatory and beneficial for health, particularly during the first years of life, due to their action in protecting against colitis, reducing pro-inflammatory cytokines such as TNF- α , IL-1, or IL-6, and increasing the subsets of regulatory T cells (90). In fact, several studies have largely described the specific action of *Lactobacilli* in maintaining the epithelial homeostasis of the gut and their striking anti-inflammatory potential (91, 92).

Nagata et al. (93) also studied the role of the gut microbiota in KS pathogenesis via SAGs and heat shock proteins (Hsps) produced by gut bacteria: the authors evaluated Sags and Hsps released by microorganisms isolated from the jejunal mucosa of 19 children with KS compared with 15 age-matched healthy controls, identifying 13 strains of Gram-negative microbes from patients with KS, which produced a large amount of Hsp60, having the power to induce an over-secretion of pro-inflammatory cytokines. They also identified 18 strains of Gram-positive cocci with SAG properties which induced the expansion of V β 2T cells *in vitro* (93). This microbiological analysis disclosed different causative bacteria with a final common pathway of immune activation, which might contribute to the final development of KS.

In order to evaluate the differential microbiota composition of KS patients, Kinumaki et al. (94) performed a metagenomic analysis using non-culture-based methods on feces. Their study included 28 KS patients (15 males and 13 females, aged 1–114 months, with a median age of 25 months); the time of admission to the study was defined as the acute phase, while 4–6 months after the onset of KS was considered as the non-acute phase. The authors collected a total of 56 samples—28 samples each for both acute and non-acute phases. It was demonstrated that the genera *Ruminococcus*, *Roseburia*, and *Faecalibacterium* were mostly predominant during the non-acute phase, while a higher presence of *Streptococcus* spp., including *Streptococcus pneumoniae*, *pseudopneumoniae*, *mitis*, *oralis*, *gordonii*, and *sanguinis*, was detected in the fecal samples during the acute phase (94).

This novel interpretation of a disease can be shared by other conditions, as liver cirrhosis and Sjögren syndrome, in which major changes of gut microbiota with higher proportions of *Streptococcus* spp. have been demonstrated (95, 96). These findings taken as a whole suggest that many other immune-mediated disorders are likely to be connected to an abnormal bacterial colonization of the intestinal tract, with a main role for *Streptococcus* spp., and that changes in the gut microflora composition might promote systemic and extra-intestinal inflammation. Therefore, all

TABLE 1 | Perturbation in the intestinal microbiota of patients with Kawasaki syndrome.

References	Methods	Site	No of patients	Results
Horita et al. (85)	Culture	Throat	21 patients with KS, 20 with other febrile illnesses	No difference
Takeshita et al. (89)	Culture	Gut	20 patients with KS, 20 patients with acute febrile diseases, 20 healthy children	↓ <i>Lactobacillus</i> , ↑ <i>Eubacterium</i> ^a , ↑ <i>Peptostreptococcus</i> ^a
Nagata et al. (93)	Culture	Gut	19 patients with KS, 15 patients with food-sensitive enteropathy in remission	↑ Gram-negative producing hsp60, ↑ Gram-positive cocci with superantigenic properties
Kinumaki et al. (94)	Metagenomic analysis on feces	Gut	28 KS patients, 28 samples during acute-phase, 28 samples in non-acute phase	↑ <i>Ruminococcus</i> ^b , ↑ <i>Roseburia</i> ^b , ↑ <i>Faecalibacterium</i> ^b , ↑ <i>Streptococcus</i> spp ^c

^aHigher in KS patients than in other febrile illness (no differences were observed between KS patients and healthy children).

^bHigher in KS patients during non-acute phase of the disease.

^cHigher in KS patients during acute phase of the disease.

presented studies confirm the concept that an imbalance in the gut microbiota might directly or indirectly interfere with the normal functions of the immune system, and that the interaction with other environmental factors, mainly infectious agents, might lead to the final development of KS.

Table 1 shows the characteristics of the microbiota in children with KS, as emerging by the most relevant studies dedicated to this issue.

CONCLUSIVE REMARKS AND FUTURE PERSPECTIVES

As no etiologic agent has ever been accused of being directly involved in the etiology of KS, basic research evaluating the pathogenic mechanisms of this disease will probably provide better therapies and probably consent to identify the most vulnerable hosts and protect them. A potential relationship between eubiosis and the protean functions of immunity has been contemplated by different studies, and conversely a relationship should exist between dysbiosis and immunity dysfunction shown by various diseases (97). It is strengthened that heterogeneity and abnormalities in the intestinal microflora composition may trigger or contribute to the development of specific diseases, and an increasing amount of research and microbiologic observations have led to a role of the intestinal microbiota for KS to be postulated. While we are becoming convinced that a role of the microbiota is likely, we do not know exactly the basic mechanism of how the microbiota should act. The principal obstacle of today's medical literature is to understand if the microbiota modification during KS can cause the disease or if it is a mark and a consequence of the disease itself, and

if modulating the microbiota/microbiome might represent a future target of therapy in KS. This raises the hypothesis of targeting intestinal microflora in order to restore eubiosis through the rational use of antibiotics, xenobiotics, probiotics and nutrients. While multicenter trials and registries may allow us to improve the general outcome of KS, further in-depth analysis in larger cohorts of affected children will probably unravel the tangled pathogenesis of this mysterious disorder and

find new targets for identifying disease-modifying agents or more specific therapies.

AUTHOR CONTRIBUTIONS

SE, IP, and DR contributed to all stages of the preparation of this manuscript, including conception and writing. All authors approved the final submitted version of the manuscript.

REFERENCES

- Chang LY, Lu CY, Shao PL, Lee PI, Lin MT, Fan TY, et al. Viral infections associated with Kawasaki disease. *J Formos Med Assoc.* (2014) 113:148–54. doi: 10.1016/j.jfma.2013.12.008
- Hedrich CM, Schnabel A, Hospach T. Kawasaki disease. *Front Pediatr.* (2018) 6:198. doi: 10.3389/fped.2018.00198
- Sehgal S, Chen X, Ang JY. Epidemiology, clinical presentation, and outcomes of Kawasaki disease among hospitalized children in an inner city hospital before and after publication of the American Academy of Pediatrics/American Heart Association Guidelines for treatment of Kawasaki disease: an 11-year period. *Clin Pediatr.* (2015) 54:1283–9. doi: 10.1177/0009922815592877
- Kawasaki T, Kosaki F, Okawa S, Shigematsu I, Yanagawa H. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. *Pediatrics.* (1974) 54:271–6.
- Marchesi A, Tarissi de Jacobis I, Rigante D, Rimini A, Malorni W, Corsello G, et al. Kawasaki disease: guidelines of the Italian Society of Pediatrics, part I—definition, epidemiology, etiopathogenesis, clinical expression and management of the acute phase. *Ital J Pediatr.* (2018) 44:102. doi: 10.1186/s13052-018-0536-3
- Marchesi A, Tarissi de Jacobis I, Rigante D, Rimini A, Malorni W, Corsello G, et al. Kawasaki disease: guidelines of Italian Society of Pediatrics, part II - treatment of resistant forms and cardiovascular complications, follow-up, lifestyle and prevention of cardiovascular risks. *Ital J Pediatr.* (2018) 44:103. doi: 10.1186/s13052-018-0529-2
- De Rosa G, Pardeo M, Rigante D. Current recommendations for the pharmacologic therapy in Kawasaki syndrome and management of its cardiovascular complications. *Eur Rev Med Pharmacol Sci.* (2007) 11:301–8.
- Rigante D, Valentini P, Rizzo D, Leo A, De Rosa G, Onesimo R, et al. Responsiveness to intravenous immunoglobulins and occurrence of coronary artery abnormalities in a single-center cohort of Italian patients with Kawasaki syndrome. *Rheumatol Int.* (2010) 30:841–6. doi: 10.1007/s00296-009-1337-1
- Rigante D, Andreozzi L, Fastiggi M, Bracci B, Natale MF, Esposito S. Critical overview of the risk scoring systems to predict non-responsiveness to intravenous immunoglobulin in Kawasaki syndrome. *Int J Mol Sci.* (2016) 17:278. doi: 10.3390/ijms17030278
- Hall GC, Tulloh LE, Tulloh RM. Kawasaki disease incidence in children and adolescents: an observational study in primary care. *Br J Gen Pract.* (2016) 66:271–6. doi: 10.3399/bjgp16X684325
- Nakamura Y, Yashiro M, Uehara R, Sadakane A, Tsuboi S, Aoyama Y, et al. Epidemiologic features of Kawasaki disease in Japan: results of the 2009–10 nationwide survey. *J Epidemiol.* (2012) 22:216–21. doi: 10.2188/jea.JE20110126
- Burgner D, Harnden A. Kawasaki disease: what is the epidemiology telling us about the aetiology? *Int J Infect Dis.* (2005) 9:185–94. doi: 10.1016/j.ijid.2005.03.002
- Principi N, Rigante D, Esposito S. The role of infection in Kawasaki syndrome. *J Infect.* (2013) 67:1–10. doi: 10.1016/j.jinf.2013.04.004
- Robinson CM, Pfeiffer JK. Viruses and the microbiota. *Annu Rev Virol.* (2014) 1:55–69. doi: 10.1146/annurev-virology-031413-085550
- Sudo D, Nakamura Y. Nationwide surveys show that the incidence of recurrent Kawasaki disease in Japan has hardly changed over the last 30 years. *Acta Paediatr.* (2017) 106:796–800. doi: 10.1111/apa.13773
- Bäckhed F, Roswall J, Peng Y, Feng Q, Jia H, Kovatcheva-Datchary P, et al. Dynamics and stabilization of the human gut microbiome during the first year of life. *Cell Host Microbe.* (2015) 17:690–703. doi: 10.1016/j.chom.2015.04.004
- Koenig JE, Spor A, Scalfone N, Fricker AD, Stombaugh J, Knight R, et al. Succession of microbial consortia in the developing infant gut microbiome. *Proc Natl Acad Sci USA.* (2011) 108:4578–85. doi: 10.1073/pnas.1000081107
- Buccigrossi V, Nicastro E, Guarino A. Functions of intestinal microflora in children. *Curr Opin Gastroenterol.* (2013) 29:31–8. doi: 10.1097/MOG.0b013e32835a3500
- Palmer C, Bik EM, Di Giulio DB, Relman DA, Brown PO. Development of the human infant intestinal microbiota. *PLoS Biol.* (2007) 5:e177. doi: 10.1371/journal.pbio.0050177
- Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, et al. Enterotypes of the human gut microbiome. *Nature.* (2011) 473:174–80. doi: 10.1038/nature09944
- Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, et al. Linking long-term dietary patterns with gut microbial enterotypes. *Science.* (2011) 334:105–8. doi: 10.1126/science.1208344
- Chen J, Ryu E, Hathcock M, Ballman K, Chia N, Olson JE, et al. Impact of demographics on human gut microbial diversity in a US Midwest population. *PeerJ.* (2016) 4:1514. doi: 10.7717/peerj.1514
- Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, et al. A core gut microbiome in obese and lean twins. *Nature.* (2009) 457:480–4. doi: 10.1038/nature07540
- Dekio I, Hayashi H, Sakamoto M, Kitahara M, Nishikawa T, Suematsu M, et al. Detection of potentially novel bacterial components of the human skin microbiota using culture-independent molecular profiling. *J Med Microbiol.* (2005) 54:1231–8. doi: 10.1099/jmm.0.46075-0
- Sakata S, Tonooka T, Ishizeki S, Takada M, Sakamoto M, Fukuyama M, et al. Culture-independent analysis of fecal microbiota in infants, with special reference to *Bifidobacterium* species. *FEMS Microbiol Lett.* (2005) 243:417–23. doi: 10.1016/j.femsle.2005.01.002
- Lee YK, Mazmanian SK. Has the microbiota played a critical role in the evolution of the adaptive immune system? *Science.* (2010) 330:1768–73. doi: 10.1126/science.1195568
- Candela M, Rampelli S, Turroni S, Severgnini M, Consolandi C, de Bellis G, et al. Unbalance of intestinal microbiota in atopic children. *BMC Microbiol.* (2012) 12:95. doi: 10.1186/1471-2180-12-95
- Siogren YM, Jenmalm MC, Botcher MF, Björkstén B, Sverremark-Ekström E. Altered early infant gut microbiota in children developing allergy up to 5 years of age. *Clin Exp Allergy.* (2009) 39:518–26. doi: 10.1111/j.1365-2222.2008.03156.x
- Aguilera M, Cerdà-Cuellar M, Martínez V. Antibiotic-induced dysbiosis alters host-bacterial interactions and leads to colonic sensory and motor changes in mice. *Gut Microbes.* (2015) 6:10–23. doi: 10.4161/19490976.2014.990790
- Davies JM, Abreu MT. Host-microbe interactions in the small bowel. *Curr Opin Gastroenterol.* (2015) 31:118–23. doi: 10.1097/MOG.0000000000000143
- Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. *Nature.* (2012) 486:207–14. doi: 10.1038/nature11234
- Alexander KL, Targan SR, Elson CO. Microbiota activation and regulation of innate and adaptive immunity. *Immunol Rev.* (2014) 260:206–20. doi: 10.1111/immr.12180
- Schwartz A, Jacobi M, Frick JS, Richter M, Rusch K, Köhler H. Microbiota in pediatric inflammatory bowel disease. *J Pediatr.* (2010) 157:240–4. doi: 10.1016/j.jpeds.2010.02.046

34. De Palma G, Nadal I, Medina M, Donat E, Ribes-Koninckx C, Calabuig M, et al. Intestinal dysbiosis and reduced immunoglobulin-coated bacteria associated with coeliac disease in children. *BMC Microbiol.* (2010) 10:63. doi: 10.1186/1471-2180-10-63
35. Schippa S, Iebba V, Barabato M, Di Nardo G, Totino V, Checchi MP, et al. A distinctive 'microbial signature' in celiac pediatric patients. *BMC Microbiol.* (2010) 10:175. doi: 10.1186/1471-2180-10-175
36. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. *Gut.* (2001) 48:206–11. doi: 10.1136/gut.48.2.206
37. Rigante D, Vitale A, Cantarini L. Autoinflammatory diseases. In: Ragab G, Atkinson TP, Stoll ML, editors. *The Microbiome in Rheumatic Diseases and Infection*. Cham: Springer International Publishing (Springer Nature) (2018). p. 371–7. doi: 10.1007/978-3-319-79026-8_28
38. Rigante D. A systematic approach to autoinflammatory syndromes: a spelling booklet for the beginner. *Expert Rev Clin Immunol.* (2017) 13:571–97. doi: 10.1080/1744666X.2017.1280396
39. Rigante D. A developing portrait of hereditary periodic fevers in childhood. *Expert Opin Orphan Drugs.* (2018) 6:47–55. doi: 10.1080/21678707.2018.1406797
40. Rigante D. The broad-ranging panorama of systemic autoinflammatory disorders with specific focus on acute painful symptoms and hematologic manifestations in children. *Mediterr J Hematol Infect Dis.* (2018) 10:e2018067. doi: 10.4084/mjhid.2018.067
41. Falcini F, Capannini S, Rigante D. Kawasaki syndrome: an intriguing disease with numerous unsolved dilemmas. *Pediatr Rheumatol Online J.* (2011) 9:17. doi: 10.1186/1546-0096-9-17
42. Rigante D, Tarantino G, Valentini P. Non-infectious makers of Kawasaki syndrome: tangible or elusive triggers? *Immunol Res.* (2016) 64:51–4. doi: 10.1007/s12026-015-8679-4
43. Rowley AH. Is Kawasaki disease an infectious disorder? *Int J Rheum Dis.* (2018) 21:20–5. doi: 10.1111/1756-185X.13213
44. Nakamura Y. Kawasaki disease: epidemiology and the lessons from it. *Int J Rheum Dis.* (2018) 21:16–9. doi: 10.1111/1756-185X.13211
45. Burns JC, Glode MP. Kawasaki syndrome. *Lancet.* (2004) 364:533–44. doi: 10.1016/S0140-6736(04)16814-1
46. Andreozzi L, Bracci B, D'Errico F, Rigante D. A master role for neutrophils in Kawasaki syndrome. *Immunol Lett.* (2017) 184:112–4. doi: 10.1016/j.imlet.2017.02.011
47. Manlihot C, Mueller B, O'Shea S, Majeed H, Bernknopf B, Labelle M, et al. Environmental epidemiology of Kawasaki disease: linking disease etiology, pathogenesis and global distribution. *PLoS ONE.* (2018) 13:e0191087. doi: 10.1371/journal.pone.0191087
48. Takeshita S, Tsujimoto H, Kawase H, Kawamura Y, Sekine I. Increased levels of lipopolysaccharide binding protein in plasma in children with Kawasaki disease. *Clin Diagn Lab Immunol.* (2002) 9:205–6. doi: 10.1128/CDLI.9.1.205-206.2002
49. Chen Y, Li X, Boini KM, Pitzer AL, Gulbins E, Zhang Y, et al. Endothelial NLRP3 inflammasome activation associated with lysosomal destabilization during coronary arteritis. *Biochim Biophys Acta.* (2015) 1853:396–408. doi: 10.1016/j.bbamcr.2014.11.012
50. Xia M, Boini KM, Abais JM, Xu M, Zhang Y, Li PL. Endothelial NLRP3 inflammasome activation and enhanced neointima formation in mice by adipokine visfatin. *Am J Pathol.* (2014) 184:1617–28. doi: 10.1016/j.ajpath.2014.01.032
51. Choi IH, Chwae YJ, Shim WS, Kim DS, Kwon DH, Kim JD, et al. Clonal expansion of CD8+ T cells in Kawasaki disease. *J Immunol.* (1997) 159:481–6.
52. Rowley AH, Wylie KM, Kim KY, Pink AJ, Yang A, Reindel R, et al. The transcriptional profile of coronary arteritis in Kawasaki disease. *BMC Genom.* (2015) 16:1076. doi: 10.1186/s12864-015-2323-5
53. Alexoudi I, Kanakis M, Kapsimali V, Vaiopoulos G. Kawasaki disease: current aspects on aetiopathogenesis and therapeutic management. *Autoimmun Rev.* (2011) 10:544–7. doi: 10.1016/j.autrev.2011.04.005
54. Rowley AH, Baker SC, Shulman ST, Rand KH, Tretiakova MS, Perlman EJ, et al. Ultrastructural, immunofluorescence, and RNA evidence support the hypothesis of a "new" virus associated with Kawasaki disease. *J Infect Dis.* (2011) 203:1021–30. doi: 10.1093/infdis/jiq136
55. Rowley AH, Baker SC, Shulman ST, Garcia FL, Fox LM, Kos IM, et al. RNA-containing cytoplasmic inclusion bodies in ciliated bronchial epithelium months to years after acute Kawasaki disease. *PLoS ONE.* (2008) 3:1582. doi: 10.1371/journal.pone.0001582
56. Rowley AH, Baker SC, Shulman ST, Fox LM, Takahashi K, Garcia FL, et al. Cytoplasmic inclusion bodies are detected by synthetic antibody in ciliated bronchial epithelium during acute Kawasaki disease. *J Infect Dis.* (2005) 192:1757–66. doi: 10.1086/497171
57. Rowley AH, Eckerley CA, Jäck HM, Shulman ST, Baker SC. IgA plasma cells in vascular tissue of patients with Kawasaki syndrome. *J Immunol.* (1997) 159:5946–55.
58. Turnier JL, Anderson MS, Heizer HR, Jone PN, Glode MP, Dominguez SR. Concurrent respiratory viruses and Kawasaki disease. *Pediatrics.* (2015) 136:609–14. doi: 10.1542/peds.2015-0950
59. Esper F, Shapiro ED, Weibel C, Ferguson D, Landry ML, Kahn JS. Association between a novel human coronavirus and Kawasaki disease. *J Infect Dis.* (2005) 191:499–502. doi: 10.1086/428291
60. Shimizu C, Shike H, Baker SC, Garcia F, van der Hoek L, Kuijpers TW, et al. Human coronavirus NL63 is not detected in the respiratory tracts of children with acute Kawasaki disease. *J Infect Dis.* (2005) 192:1767–71. doi: 10.1086/497170
61. Chua PK, Nerurkar VR, Yu Q, Woodward CL, Melish ME, Yanagihara R. Lack of association between Kawasaki syndrome and infection with parvovirus B19, human herpes-virus 8, TT virus, GB virus C/hepatitis G virus or *Chlamydia pneumoniae*. *Pediatr Infect Dis J.* (2000) 19:477–9. doi: 10.1097/00006454-200005000-00019
62. Kanegane H, Tsuji T, Seki H, Yachie A, Yokoi T, Miyawaki T, et al. Kawasaki disease with a concomitant primary Epstein-Barr virus infection. *Acta Paediatr Jpn.* (1994) 36:713–6. doi: 10.1111/j.1442-200X.1994.tb03277.x
63. Embil JA, McFarlane ES, Murphy DM, Krause VW, Stewart HB. Adenovirus type 2 isolated from a patient with fatal Kawasaki disease. *Can Med Assoc J.* (1985) 132:1400.
64. Hagiwara K, Komura H, Kishi F, Kaji T, Yoshida T. Isolation of human herpesvirus-6 from an infant with Kawasaki disease. *Eur J Pediatr.* (1992) 152:176. doi: 10.1007/BF02072502
65. Kuijpers TW, Herweijer TJ, Scholvinck L, Wertheim-Van Dillen PM, Van De Veer EM. Kawasaki disease associated with measles virus infection in a monozygotic twin. *Pediatr Infect Dis J.* (2000) 19:350–3. doi: 10.1097/00006454-200004000-00018
66. Johnson D, Azimi P. Kawasaki disease associated with *Klebsiella pneumoniae* bacteremia and parainfluenza type 3 virus infection. *Pediatr Infect Dis J.* (1985) 4:100. doi: 10.1097/00006454-198501000-00024
67. Sopontammarak S, Pruekprasert P. Concomitant dengue hemorrhagic fever with Kawasaki disease. *Southeast Asian J Trop Med Public Health.* (2000) 31:190–2.
68. Joshi AV, Jones KD, Buckley AM, Coren ME, Kampmann B. Kawasaki disease coincident with influenza A H1N1/09 infection. *Pediatr Int.* (2011) 53:e1–2. doi: 10.1111/j.1442-200X.2010.03280.x
69. Rigante D, Cantarini L, Piastra M, Angelone DF, Valentini P, Pardeo M, et al. Kawasaki syndrome and concurrent Coxsackie-virus B3 infection. *Rheumatol Int.* (2012) 32:4037–40. doi: 10.1007/s00296-010-1613-0
70. Song E, Kajon AE, Wang H, Salamon D, Texter K, Ramilo O, et al. Clinical and virologic characteristics may aid distinction of acute adenovirus disease from Kawasaki disease with incidental adenovirus detection. *J Pediatr.* (2016) 170:325–30. doi: 10.1016/j.jpeds.2015.11.021
71. Jaggi P, Kajon AE, Mejias A, Ramilo O, Leber A. Human adenovirus infection in Kawasaki disease: a confounding bystander? *Clin Infect Dis.* (2013) 56:58–64. doi: 10.1093/cid/cis807
72. Usta Guç B, Cengiz N, Yildirim SV, Uslu Y. Cytomegalovirus infection in a patient with atypical Kawasaki disease. *Rheumatol Int.* (2008) 28:387–9. doi: 10.1007/s00296-007-0440-4
73. Bajolle F, Meritet JF, Rozenberg F, Chalumeau M, Bonnet D, Gendrel D, et al. Markers of a recent bocavirus infection in children with Kawasaki disease: "A year prospective study". *Pathol Biol.* (2014) 62:365–8. doi: 10.1016/j.patbio.2014.06.002

74. Yoshioka T, Matsutani T, Iwagami S, Toyosaki-Maeda T, Yutsudo T, Tsuruta Y, et al. Polyclonal expansion of TCRBV2- and TCRBV6-bearing T cells in patients with Kawasaki disease. *Immunology*. (1999) 96:465–72. doi: 10.1046/j.1365-2567.1999.00695.x
75. Leung DYM, Meissner HC, Shulman ST, Mason WH, Gerber MA, et al. Prevalence of superantigen-secreting bacteria in patients with Kawasaki disease. *J Pediatr*. (2002) 140:742–6. doi: 10.1067/mpd.2002.123664
76. Matsubara K, Fukaya T, Miwa K, Shibayama N, Nigami H, Harigaya H, et al. Development of serum IgM antibodies against superantigens of *Staphylococcus aureus* and *Streptococcus pyogenes* in Kawasaki disease. *Clin Exp Immunol*. (2006) 143:427–34. doi: 10.1111/j.1365-2249.2006.03015.x
77. Matsubara K, Fukaya T. The role of superantigens of group A *Streptococcus* and *Staphylococcus aureus* in Kawasaki disease. *Curr Opin Infect Dis*. (2007) 20:298–303. doi: 10.1097/QCO.0b013e3280964d8c
78. Suenaga T, Suzuki H, Shibuta S, Takeuchi T, Yoshikawa N. Detection of multiple superantigen genes in stools of patients with Kawasaki disease. *J Pediatr*. (2009) 155:266–70. doi: 10.1016/j.jpeds.2009.03.013
79. Lee MN, Cha JH, Ahn HM, Yoo JH, Kim HS, Sohn S, et al. *Mycoplasma pneumoniae* infection in patients with Kawasaki disease. *Korean J Pediatr*. (2011) 54:123–7. doi: 10.3345/kjp.2011.54.3.123
80. Rodo X, Curcoll R, Robinson M, Ballester J, Burns JC, Cayan DR, et al. Tropospheric winds from northeastern China carry the etiologic agent of Kawasaki disease from its source to Japan. *Proc Natl Acad Sci USA*. (2014) 111:7952–7. doi: 10.1073/pnas.1400380111
81. Sato W, Ishibashi KI, Yamanaka D, Adachi Y, Ohno N. Effects of natural and chemically defined nutrients on *Candida albicans* water-soluble fraction (CAWS) vasculitis in mice. *Med Mycol J*. (2017) 58:E47–62. doi: 10.3314/mmj.16-00014
82. Ishida-Okawara A, Nagi-Miura N, Oharaseki T, Takahashi K, Okumura A, Tachikawa H, et al. Neutrophil activation and arteritis induced by *C. albicans* water-soluble mannoprotein-beta-glucan complex (CAWS). *Exp Mol Pathol*. (2007) 82:220–6. doi: 10.1016/j.yexmp.2006.05.006
83. Nagi-Miura N, Shingo Y, Adachi Y, Ishida-Okawara A, Oharaseki T, Takahashi K, et al. Induction of coronary arteritis with administration of CAWS (*Candida albicans* water-soluble fraction) depending on mouse strains. *Immunopharmacol Immunotoxicol*. (2004) 26:527–43. doi: 10.1081/IPH-200042295
84. Lee KY, Han JW, Lee JS. Kawasaki disease may be a hyperimmune reaction of genetically susceptible children to variants of normal environmental flora. *Med Hypotheses*. (2007) 69:642–51. doi: 10.1016/j.mehy.2006.12.051
85. Horita N, Yokota S, Fuse S, Takamuro M, Tomita H, Sato K, et al. The throat flora and its mitogenic activity in patients with Kawasaki disease. *Microbiol Immunol*. (2004) 48:899–903. doi: 10.1111/j.1348-0421.2004.tb03609.x
86. Yamashiro Y, Nagata S, Ohtsuka Y, Oguchi S, Shimizu T. Microbiologic studies on the small intestine in Kawasaki disease. *Pediatr Res*. (1996) 39:622–4. doi: 10.1203/00006450-199604000-00010
87. Nagata S, Yamashiro Y, Maeda M, Ohtsuka Y, Yabuta K. Immunohistochemical studies on small intestinal mucosa in Kawasaki disease. *Pediatr Res*. (1993) 33:557–63. doi: 10.1203/00006450-199306000-00004
88. Eladawy M, Dominguez SR, Anderson MS, Glodé MP. Kawasaki disease and the pediatric gastroenterologist: a diagnostic challenge. *J Pediatr Gastroenterol Nutr*. (2013) 56:297–99. doi: 10.1097/MPG.0b013e3182794432
89. Takeshita S, Kobayashi I, Kawamura Y, Tokutomi T, Sekine I. Characteristic role of intestinal microflora in Kawasaki disease. *Acta Pediatr*. (2001) 91:783–88. doi: 10.1111/j.1651-2227.2002.tb03327.x
90. Reading NC, Kasper DL. The starting lineup: key microbial players in intestinal immunity and homeostasis. *Front Microbiol*. (2011) 2:148. doi: 10.3389/fmicb.2011.00148
91. Macho Fernandez E, Valenti V, Rockel C, Hermann C, Pot B, Boneca IG, et al. Anti-inflammatory capacity of selected lactobacilli in experimental colitis is driven by NOD2-mediated recognition of a specific peptidoglycan-derived muropeptide. *Gut*. (2011) 60:1050–9. doi: 10.1136/gut.2010.232918
92. Tien MT, Girardin SE, Regnault B, Le Bourhis L, Dillies MA, Coppée JY, et al. Anti-inflammatory effect of *Lactobacillus casei* on Shigella-infected human intestinal epithelial cells. *J Immunol*. (2006) 176:1228–37. doi: 10.4049/jimmunol.176.2.1228
93. Nagata S, Yamashiro Y, Ohtsuka Y, Shimizu T, Sakurai Y, Misawa S, et al. Heat shock proteins and superantigenic properties of bacteria from the gastrointestinal tract of patients with Kawasaki disease. *Immunology*. (2009) 125:11–20. doi: 10.1111/j.1365-2567.2009.03135.x
94. Kinumaki A, Sekizuka T, Hamada H, Kato K, Yamashita A, Kuroda M. Characterization of the gut microbiota of Kawasaki disease patients by metagenomic analysis. *Front Microbiol*. (2015) 6:824. doi: 10.3389/fmicb.2015.00824
95. De Paiva CS, Jones DB, Stern ME, Bian F, Moore QL, Corbiere S, et al. Altered mucosal microbiome diversity and disease severity in Sjögren syndrome. *Sci Rep*. (2016) 6:23561. doi: 10.1038/srep23561
96. Qin N, Yang F, Li A, Prifti E, Chen Y, Shao L, et al. Alterations of the human gut microbiome in liver cirrhosis. *Nature*. (2014) 513:59–64. doi: 10.1038/nature13568
97. Iebba V, Totino V, Gagliardi A, Santangelo F, Cacciotti F, Trancassini M, et al. Eubiosis and dysbiosis: the two sides of the microbiota. *N Microbiol*. (2016) 39:1–12.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Esposito, Polinori and Rigante. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.